Workflow
业绩增长
icon
Search documents
都乐食品股价近期走弱,机构仍看好其业绩增长
Jing Ji Guan Cha Wang· 2026-02-11 15:29
经济观察网截至2026年2月11日收盘,都乐食品(DOLE.N)股价报收15.66美元,近7日(2月5日至11日)累 计下跌4.34%,区间振幅为5.80%。期间最高价为2月6日的16.57美元,最低价为2月11日的15.62美元。 成交量呈现波动,2月5日和6日成交活跃,但2月11日成交量显著下降,显示交投趋于清淡。同期所属农 产品板块上涨0.96%,美股大盘道琼斯指数下跌0.35%,公司股价表现弱于板块及大盘。 机构观点 2026年2月,机构评级显示5家机构中60%给予"买入或增持"观点,目标均价17.50美元。盈利预测方面, 机构预计2025年第四季度每股收益0.127美元,同比增长64.94%;2025年全年营收预计同比增长 12.45%,增长动力或逐步从价格驱动转向销量驱动。 以上内容基于公开资料整理,不构成投资建议。 ...
麦克森发布2026财年Q3财报,业绩超预期股价活跃
Jing Ji Guan Cha Wang· 2026-02-11 15:26
近期事件 经济观察网 麦克森于2026年2月4日发布2026财年第三季度财报(截至2025年12月31日)。根据财报数 据,季度营业收入为1061.58亿美元,同比增长11.40%;归母净利润为11.86亿美元,同比增长34.93%; 净利率为1.12%。公司同时上调了全年每股收益指引,反映出对业务增长的信心。肿瘤与多专科业务表 现亮眼,收入同比增长31.5%,成为关键增长引擎。 机构观点 多家华尔街机构近期更新对麦克森的评级。TD Cowen于2026年2月5日维持买入评级,并将目标价从 1000美元上调至1012美元。富国集团、Evercore、瑞穗证券和贝雅等机构在2月6日集中调整目标价,区 间为885美元至1000美元,其中Evercore维持1000美元的最高目标价。当前机构目标均价为980.47美元, 较最新股价有潜在上行空间。 股票近期走势 近7天麦克森股价波动显著。2026年2月5日,股价单日大涨16.52%至957.80美元,成交额达21.35亿美 元,显示市场对财报的积极反应;2月6日股价微跌0.95%,但成交额仍维持11.28亿美元的高位;2月9日 股价反弹1.44%至962.32美元; ...
泛林集团财报超预期,股价大涨,董事减持引关注
Jing Ji Guan Cha Wang· 2026-02-11 14:44
机构观点 2月8日,多家分析师给予泛林集团"强力推荐"评级,看好其业绩增长和行业前景。 近期事件 根据美国证券交易委员会文件披露,董事BRANDT ERIC于2月6日以每股平均价225.6美元售出3.5万股 公司股份,价值约789.62万美元。 经济观察网 泛林集团发布2026财年第二季度财报,营收达53.45亿美元,同比增长22.14%,超出市场预 期;净利润为15.94亿美元,同比增长33.83%,超出预期。公司第三季度业绩指引强劲,预计营收在54 亿至60亿美元之间,每股收益在1.25至1.45美元之间,均显著高于市场预期。 财报分析 根据富途资讯的报道,泛林集团于2026年1月28日发布的2026财年第二季度财报显示,营收达53.45亿美 元,同比增长22.14%,超出市场预期1.05亿美元;净利润为15.94亿美元,同比增长33.83%,超出预期 1.32亿美元。公司第三季度业绩指引强劲,预计营收在54亿至60亿美元之间,每股收益在1.25至1.45美 元之间,均显著高于市场预期。 股票近期走势 近7个交易日,泛林集团股价受财报利好驱动波动显著。2月6日财报公布后,股价单日大涨8.30%至 231. ...
福斯2025财年净利润增长22.45%,股价近期表现活跃
Jing Ji Guan Cha Wang· 2026-02-11 14:22
机构观点 机构评级方面,截至2026年2月,14家机构中71%给予"买入"或"增持"观点,目标均价为92.10美元,较 当前股价(86.59美元)存在一定溢价。盈利预测显示,2025年第四季度每股收益预计为0.938美元,同比 增长58.57%,反映机构对业绩增长持乐观预期。 经济观察网福斯于2026年2月5日发布2025财年年报。财报显示,全年营业收入达47.29亿美元,同比增 长3.76%;归母净利润为3.46亿美元,同比增长22.45%;净利率为7.32%,毛利率为33.45%。基本每股 收益为2.66美元,同比增长约24%。公司资产负债率为60.51%,流动比率为2.03,整体财务结构稳健。 财报分析 近7天(截至2026年2月10日),福斯股价波动显著。2月6日单日大涨8.20%,收盘价报85.46美元;2月10日 最新收盘价为86.59美元,单日涨幅1.14%。区间累计上涨8.56%,振幅达13.33%,最高价为87.66美元(2 月10日)。成交额方面,2月6日成交2.78亿美元,换手率2.58%,显示资金活跃度提升。同期,美股标普 500指数上涨0.86%,公司股价表现优于大盘。 以上内容基于 ...
伍德沃德一季度业绩强劲,股价波动上行获机构看好
Jing Ji Guan Cha Wang· 2026-02-11 13:54
2026财年第一季度财报显示,伍德沃德单季收入9.96亿美元,同比增长28.95%;净利润1.34亿美元,同 比增长53.54%。增长主要受航空航天板块驱动,该板块营收同比增长20%,国防OEM业务及商业服务 需求旺盛。公司同时给出乐观的2026财年业绩指引,预计全年销售额增长7%-12%。 基于内部数据库,近一周(2026年2月5日至10日)伍德沃德股价呈现波动上行态势。区间累计涨幅 4.88%,振幅达10.26%,最高价触及403.31美元(2月9日),最低价为364.99美元(2月5日)。成交额方面,2 月10日单日成交2.79亿美元,换手率1.20%,显示市场交投活跃。 财报分析 机构观点 经济观察网伍德沃德(WWD.OQ)于2026年2月2日盘后发布2026财年第一季度(截至2025年12月31日)财 报,报告期内业绩表现强劲,收入与盈利均实现大幅增长。该事件是近期影响股价的核心因素。 根据机构数据,截至2026年2月,多家机构对伍德沃德维持积极看法,目标均价为420美元,最高目标价 达450美元。机构评级中买入或增持占比75%,反映市场对公司在航空航天及工业控制领域前景的认 可。 股票近期走势 以 ...
创新软件将发布2026财年一季报,市场预期业绩高增长
Jing Ji Guan Cha Wang· 2026-02-11 13:54
经济观察网 创新软件(ISSC.OQ)计划于美东时间2月12日盘前公布2026财年第一季度业绩。机构预期 营收为1881.50万美元,同比增长17.82%;每股收益为0.13美元,同比增长225.0%。 股票近期走势 近7天(2026年2月5日至10日),公司股价呈现波动上行态势,区间涨幅为5.52%,振幅达12.82%。2月 5日收盘价为18.03美元,2月6日大幅反弹至19.59美元,2月9日收于19.89美元,2月10日微调至19.68美 元。区间成交额约2247.76万美元,换手率温和,市场活跃度逐步提升。 财报分析 机构对即将发布的业绩持乐观预期,预计营收和每股收益均实现双位数高增长。此预期基于公司2025财 年(截止2025年9月30日)的财务表现:营收同比增长78.60%,净利润同比增长123.30%,毛利率达 45.43%,显示盈利能力和成长性持续改善。 机构观点 板块层面,瑞银环球财富管理于2月10日将标普500信息技术板块评级从"具有吸引力"下调至"中性",指 出超大规模企业资本支出增速可能放缓,或对软件行业带来不确定性。这一调整可能间接影响创新软件 等科技股的市场情绪。 以上内容基于公开 ...
百奥赛图-B午后上涨,25年业绩预告亮眼,机构称对外授权打开长期增长天花板
Zhi Tong Cai Jing· 2026-02-11 09:14
Core Viewpoint - The company BaiO Saite-B (02315) has seen a significant stock increase of over 6% following the release of its 2025 performance forecast, indicating strong growth potential in revenue and net profit [1] Group 1: Financial Performance - BaiO Saite-B forecasts annual revenue for 2025 to be approximately 1.369 billion to 1.389 billion yuan, representing a year-on-year growth of 39.61% to 41.65% [1] - The expected net profit attributable to shareholders is projected to be around 162 million to 182 million yuan, showing a substantial year-on-year increase of 384.26% to 443.88% [1] Group 2: Market Position and Growth Drivers - According to Guolian Minsheng Securities, the company's strong performance is attributed to its innovative advantages in model animals and preclinical CRO business, as well as the antibody platform supported by the "Thousand Mice and Ten Thousand Antibodies" initiative [1] - The company has established partnerships with several leading domestic and international pharmaceutical companies since 2025, and multiple pipelines have received IND approvals, which are expected to generate milestone payments and further enhance growth potential [1]
网易:Q4营业利润83亿元,同比增长6%
Ge Long Hui A P P· 2026-02-11 09:00
Core Insights - NetEase reported steady performance for Q4 2025, with revenue reaching 27.5 billion yuan and total annual revenue of 112.6 billion yuan [1] - The company achieved an operating profit of 35.8 billion yuan for the year, reflecting a year-on-year growth of 21%, while Q4 operating profit was 8.3 billion yuan, up 6% year-on-year [1] - Research and development investment reached 17.7 billion yuan, marking the sixth consecutive year of R&D spending exceeding 10 billion yuan [1] - The net income from games and related value-added services was 92.1 billion yuan, with online gaming net income at 89.6 billion yuan, showing an 11% year-on-year increase [1]
张小泉2025年业绩预增超90%,控股权变更引关注
Jing Ji Guan Cha Wang· 2026-02-11 07:20
Core Viewpoint - Zhang Xiaoqin has released a performance forecast for 2025, expecting a significant net profit increase of 91.67% to 171.53%, driven by strategic deepening, supply chain optimization, and e-commerce channel expansion [1][2]. Group 1: Performance and Business Operations - The company anticipates a net profit attributable to shareholders of between 48 million to 68 million yuan for 2025, reflecting a year-on-year growth of 91.67% to 171.53% [2]. - The growth is primarily attributed to the deepening of operational strategies, optimization of the supply chain, and expansion of e-commerce channels [2]. Group 2: Company Structure and Governance - Due to changes in shareholder structure, Zhang Xiaoqin Group is no longer classified as having a controlling shareholder, with the actual controller status changing to "no actual controller" [3]. - The current largest shareholder holds a 29.99% stake, which is close to the previous controlling shareholder's stake, indicating uncertainty in the equity structure [3]. Group 3: Capital Movements - A specific shareholder, Hangzhou Zhenquan Investment Partnership, plans to reduce its holdings by up to 0.32% of the total share capital, equivalent to approximately 477,200 shares, from February 10 to May 9, 2026, due to funding needs [4]. - This reduction plan may impact short-term market sentiment [4].
新宙邦(300037)2025年业绩快报点评:氟化工稳中有升 六氟涨价盈利修复
Xin Lang Cai Jing· 2026-02-11 06:44
Core Viewpoint - The company is expected to achieve revenue of 9.64 billion yuan in 2025, representing a year-on-year increase of 22.8%, with a projected net profit attributable to shareholders of 1.1 billion yuan, up 16.6% year-on-year, and a non-recurring net profit of 1.09 billion yuan, up 14.5% year-on-year [1] Group 1: Financial Performance - The company forecasts a net profit of 350 million yuan for Q4 2025, with a quarter-on-quarter increase of 45.5% and a year-on-year increase of 32.5% [1] - The estimated non-recurring net profit for Q4 2025 is 370 million yuan, with a quarter-on-quarter increase of 53% and a year-on-year increase of 50% [1] - The company expects to ship over 80,000 tons of electrolyte in Q4 2025, a 35% year-on-year increase, and over 280,000 tons for the entire year, a 45% increase [1] Group 2: Profitability and Market Dynamics - The electrolyte segment is projected to contribute approximately 100 million yuan in profit for Q4, with a unit profit recovery to 1,200 yuan per ton, primarily driven by price increases in hexafluorophosphate and VC [1] - The company anticipates that the fluorochemical segment will generate around 200 million yuan in profit for Q4 2025, with a slight increase quarter-on-quarter [2] - The semiconductor cooling liquid product is expected to complete customer certification in 2026, leading to volume growth, while the fluorochemical segment is projected to contribute 1 billion yuan in profit, indicating a recovery in growth [2] Group 3: Investment Outlook - The company maintains a "buy" rating, with a target price of 79.8 yuan, based on significant price increases for hexafluorophosphate and VC, and expected contributions from new products in the fluorochemical business [2] - The projected net profits for 2025, 2026, and 2027 are 1.1 billion, 2.4 billion, and 2.98 billion yuan respectively, reflecting year-on-year growth of 17%, 118%, and 25% [2]